Stifel raised the firm’s price target on Kestra Medical (KMTS) to $30 from $28 and keeps a Buy rating on the shares. Coming in at the high-end of the company’s December 1st preannounced sales range, Kestra reported Q2 sales at $22.6M also accelerated gross margins to about 51%, the firm notes. Stifel also points out that encouragingly, management raised full-year 2026 sales guidance to $91M from $88M, previously. As expected, this broadly positive quarterly performance was underpinned by continued ASSURE wearable cardioverter defibrillator share gains and broader market expansion.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Morning Movers: Cannabis stocks higher after reports of reclassification
- Kestra Medical price target raised to $28 from $27 at Wells Fargo
- Kestra Medical price target raised to $30 from $27 at Piper Sandler
- Kestra Medical Technologies: Strong Financial Performance and Market Leadership Drive Buy Rating
- Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%